# MOTS-c – 40mg/vial (Research Use Only)

**Independent lab result · batch PTW-MOTSC40-2608-001**

MOTS-c 40mg. Tested by Janoshik Analytical (task #243315), analysis conducted 23 Oct 2026. The sample was pulled from our own stock, submitted and paid for by Portal to Wellness, and the report names us as the client.

- Identity: MOTS-c, confirmed by MOTS-c analysis
- Measured content: 44.65 mg per vial (labelled 40 mg)
- Purity: 98.940% (HPLC)

[View and verify the full report on Janoshik’s site →](https://verify.janoshik.com/tests/243315-MOTSc_40mg_VY3JEDAMVGGB)

This result applies to batch PTW-MOTSC40-2608-001. The batch number is printed on the vial label. See all published results on our [Lab Testing & Verification](https://portaltowellness.net/lab-verification-quality-testing/) page.

## Overview

Backed by the Research [Read: How Incretin and Growth-Hormone-Axis Compounds in the Literature →](https://portaltowellness.net/research/glp1-adjunct-peptide-research-guide/) [Read: MOTS-c: The Mitochondrial-Derived Peptide Explained →](https://portaltowellness.net/research/mots-c-mitochondrial-peptide-research/)

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid mitochondria-derived peptide (MDP) encoded within the 12S rRNA gene of the mitochondrial genome. Since its discovery at USC, MOTS-c has generated significant research interest as a metabolic regulator with exercise-mimetic properties in preclinical models. Published research has examined its role in AMPK pathway activation, folate cycle modulation, and systemic metabolic programming, positioning it alongside humanin as a founding member of the mitochondrial peptide research field.

## What It Is

MOTS-c is a 16-amino acid peptide with the sequence MRWQEMGYIFYPRKLR and MW approximately 2,174 Da, encoded within the 12S rRNA gene of human mitochondrial DNA. CAS number: 1627580-64-6. MOTS-c translocates to the nucleus under metabolic stress conditions and regulates AMPK activation, folate/methionine cycle modulation, and antioxidant response elements.

## Key Research Applications

- Mitochondria-derived peptide (MDP) biology and mtDNA-encoded signaling research
- AMPK activation, metabolic sensing, and cellular energy homeostasis studies
- Folate cycle and one-carbon metabolism regulation research
- Exercise-mimetic pharmacology and skeletal muscle metabolic programming studies
- Insulin sensitivity, glucose utilization, and metabolic flexibility research
- Nuclear translocation and mitochondrial-nuclear communication studies
- Age-associated metabolic parameter research — MOTS-c plasma level dynamics in aged animal models
- Comparative MDP research alongside Humanin and other mitochondrial peptides

## Technical Specifications

| **Amino Acids** | 16 (MRWQEMGYIFYPRKLR) |
| --- | --- |
| **Molecular Weight** | ~2,174 Da |
| **CAS Number** | 1627580-64-6 |
| **Origin** | Mitochondrial 12S rRNA gene-encoded peptide (mtDNA) |
| **Mechanism** | AMPK Activator; Folate Cycle Regulator; Metabolic Reprogrammer |
| **Purity** | ≥98% (supplier specification) |
| **Form** | Lyophilized powder |
| **Vial Size** | 40mg |

*For laboratory research use only. Not intended for human or veterinary use, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting.*

Not sure which compounds fit your research? [Browse the Research Hub →](https://portaltowellness.net/research/)

### Related research (educational)

- [Overlapping Pathways in Circadian, Repair and Mitochondrial Biology](https://portaltowellness.net/research/sleep-repair-energy-one-system/)
- [MOTS-c: The Mitochondrial-Derived Peptide Explained](https://portaltowellness.net/research/mots-c-mitochondrial-peptide-research/)
- [Why Researchers Study NAD+: Energy, Longevity & the Hallmarks of Aging](https://portaltowellness.net/research/nad-plus-benefits-research/)

Regulatory Status Note

On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee reviewed whether BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and emideltide (DSIP) should be added to the 503A Bulks List for pharmacy compounding. The committee voted to recommend six of the seven; emideltide (DSIP) was **not** recommended. FDA’s own briefing documents had recommended against all seven.

A committee vote is a recommendation only. It does not constitute FDA approval, does not establish safety or effectiveness, and does not change the status of this product, which is sold strictly for research use. FDA must complete formal rulemaking before any substance is added to the list. [Source: FDA Advisory Committee Calendar](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) . Last reviewed: August 17, 2026.

**Update (July 22, 2026):** FDA has posted its scientific briefing documents for the July 23–24 committee meeting. FDA staff are recommending against adding MOTS-c to the 503A Bulks List, alongside six other reviewed peptides, citing gaps in characterization, effectiveness, and human safety data — consistent with the human-exposure-data gap already noted above.

At a Glance: Four Separate Questions

- **Research status:** Sold for research/laboratory use only, not as a consumer drug.
- **Compounding status:** An FDA advisory committee recommended possible inclusion on the 503A Bulks List (non-binding). FDA has not issued a final decision.
- **FDA approval status:** Not FDA-approved for any use.
- **Evidence status:** Early-stage research on mitochondrial function and energy metabolism; FDA has stated no human exposure data has been identified for any route of administration.

Last reviewed: August 9, 2026 — status unchanged (still an advisory committee recommendation; not final 503A inclusion or FDA approval). See our [full explainer on these four categories](https://portaltowellness.net/research/compounded-peptide-vs-research-peptide/) .

Research Library

- [BPC-157, TB-500 and MOTS-c: Inside the FDA’s July 2026 Compounding Review](https://portaltowellness.net/research/fda-peptide-review-july-2026/)
- [FDA PCAC July 2026: BPC-157, TB-500, and MOTS-c Under Official Review](https://portaltowellness.net/research/fda-peptide-review-july-2026/)
- [BPC-157, TB-500, and MOTS-c Under FDA Advisory Review: What Researchers Need to Know](https://portaltowellness.net/research/fda-peptide-review-july-2026/)
- [FDA’s July 2026 503A Review: What It Means for BPC-157, TB-500, and MOTS-c Researchers](https://portaltowellness.net/research/fda-peptide-review-july-2026/)
- [What the July 2026 FDA Compounding Advisory Committee Means for Peptide Researchers](https://portaltowellness.net/research/fda-peptide-review-july-2026/)

**Update — July 24, 2026:** On July 23, the committee voted. BPC-157, KPV, and TB-500 each passed 8-6 with one abstention; MOTS-c passed 7-5 with two abstentions. The recommendation is non-binding — FDA is not required to follow it, must still issue a formal decision, and the process may require additional rulemaking before any compounding pharmacy could act on it. No peptide has been FDA-approved, and this update does not constitute or imply a therapeutic claim. [Source: STAT News](https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/)

---

Source: https://portaltowellness.net/shop/mots-c-40mg-vial/
Research use only. Terms: https://portaltowellness.net/research-use-only/